• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Lake Street initiated coverage on Assertio Therapeutics with a new price target

    11/7/22 9:24:08 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASRT alert in real time by email
    Lake Street initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $7.00
    Get the next $ASRT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ASRT

    DatePrice TargetRatingAnalyst
    7/26/2024$3.00Buy
    Maxim Group
    7/3/2024$4.00Buy
    H.C. Wainwright
    11/7/2022$7.00Buy
    Lake Street
    More analyst ratings

    $ASRT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO O'Grady Brendan P. converted options into 166,665 shares and covered exercise/tax liability with 49,416 shares, increasing direct ownership by 1,002% to 128,955 units (SEC Form 4)

      4 - Assertio Holdings, Inc. (0001808665) (Issuer)

      6/3/25 6:00:13 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, General Counsel Schlessinger Sam converted options into 38,017 shares and covered exercise/tax liability with 14,958 shares, increasing direct ownership by 15% to 176,948 units (SEC Form 4)

      4 - Assertio Holdings, Inc. (0001808665) (Issuer)

      5/14/25 6:03:08 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Schwichtenberg Paul converted options into 38,017 shares and covered exercise/tax liability with 16,840 shares, increasing direct ownership by 14% to 167,522 units (SEC Form 4)

      4 - Assertio Holdings, Inc. (0001808665) (Issuer)

      5/14/25 6:01:08 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASRT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Assertio Therapeutics with a new price target

      Maxim Group initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $3.00

      7/26/24 7:49:44 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Assertio Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $4.00

      7/3/24 7:25:55 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lake Street initiated coverage on Assertio Therapeutics with a new price target

      Lake Street initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $7.00

      11/7/22 9:24:08 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASRT
    SEC Filings

    See more
    • SEC Form S-8 filed by Assertio Holdings Inc.

      S-8 - Assertio Holdings, Inc. (0001808665) (Filer)

      5/19/25 4:18:53 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assertio Holdings Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Assertio Holdings, Inc. (0001808665) (Filer)

      5/13/25 4:30:23 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Assertio Holdings Inc.

      10-Q - Assertio Holdings, Inc. (0001808665) (Filer)

      5/12/25 5:01:53 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASRT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Assertio to Participate in the Alliance Global Partners Healthcare Company Showcase on May 21, 2025

      LAKE FOREST, Ill., May 19, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that Brendan O'Grady, Chief Executive Officer, will present at the virtual Alliance Global Partners Healthcare Company Showcase, taking place Wednesday, May 21, 2025. Mr. O'Grady's fireside chat will be webcast live at 11:20 a.m. ET. To join the event, please register at https://us02web.zoom.us/webinar/register/WN_jB1HgKLvQFmUfC6VBT11mw#/registration, or visit the Events & Presentations page at the Company's investor relations website, https://investor.assertiotx.com/. About Assertio Assertio is a pharmaceutical company with comprehensive commercial cap

      5/19/25 4:10:00 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025

      LAKE FOREST, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it will release first quarter 2025 financial results on Monday, May 12, 2025, after the market close. Additionally, Assertio's management will host a live webcast conference call at 4:30 p.m. Eastern Time to discuss the financial results and update the Company's 2025 strategic plans. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate tim

      5/5/25 8:15:00 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025

      LAKE FOREST, Ill., March 20, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that Brendan O'Grady, Chief Executive Officer, will present at the iAccess Alpha Best Ideas Spring Investment Conference taking place virtually March 25-26, 2025. The Company will present at 1:30 pm Eastern Time on Tuesday, March 25, 2025. To join the presentation, please visit the webcast available online at https://investor.assertiotx.com/. Additionally, investors participating in the conference can request 1x1 meetings to take place on March 26, 2025 via their conference representative or through Assertio investor relations at [email protected]. T

      3/20/25 9:10:00 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASRT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mason Heather L bought $60,000 worth of shares (75,000 units at $0.80), increasing direct ownership by 35% to 287,650 units (SEC Form 4)

      4 - Assertio Holdings, Inc. (0001808665) (Issuer)

      11/19/24 9:02:18 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO O'Grady Brendan P. bought $9,950 worth of shares (11,706 units at $0.85) (SEC Form 4)

      4 - Assertio Holdings, Inc. (0001808665) (Issuer)

      11/15/24 2:43:25 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Vacirca Jeff L bought $11,100 worth of shares (10,000 units at $1.11), increasing direct ownership by 7% to 151,159 units (SEC Form 4)

      4 - Assertio Holdings, Inc. (0001808665) (Issuer)

      6/12/24 6:00:09 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care